Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant as Adjunctive Therapy in MDD With Insomnia Symptoms
NCT06559306Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Jul 2024; status: recruiting.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06559306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559306.